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Abstract BRAFV600E mutation, usually performed by DNA
techniques, is one of the most common diagnostic markers
in papillary thyroid carcinoma. Few papers have demon-
strated that plump cells (eosinophilic cytoplasms and
papillary thyroid carcinoma nuclei) and peculiar sickle-
shaped nuclei represent morphological features of
BRAFV600E on papillary thyroid carcinomas. These features
seem to be linked to glycolytic phenotype whereby
monocarboxylate transporters 1–4 are hypothesized to have
a dominant role as lactate transporters. We investigated the
association between these morphological features and
monocarboxylate transporters 1 and 4 in 48 cyto-
histological samples diagnosed as “positive for
malignancy-favoring papillary thyroid carcinoma”. These
cases were processed with liquid-based cytology and
underwent BRAFV600E mutational analysis (pyrosequen-
cing) on liquid-based cytology and monocarboxylate
transporters immunostaining on histology. The expression
of monocarboxylate transporter 1, monocarboxylate trans-
porter 4, glucose trasporter-1 and carbonic anhidrase were
scored semi-quantitatively with expression from 0 to 3+
(strong positivity). The 33 mutated and 15 wild type cases
showed 100% cyto-histological concordance. The cytolo-
gical evaluation revealed plump cells and sickle nuclear
shape in 100 % mutated cases. Monocarboxylate transporter
1 yielded 76% positivity in the mutated cases especially in
both the plump cells and sickle-shaped nuclei, whereas the
wild types showed 13.3 % positive monocarboxylate
transporter 1 (p= 0.00013). Monocarboxylate transporter 4
resulted in 100 % positivity in mutated and 40 % in wild
types (p< 0.005). Furthermore, 20 % of the wild types
showed weak monocarboxylate transporter 1 nuclear
expression associated to a less aggressive behavior. The
analysis of glucose trasporter-1 and carbonic anhidrase did
not highlight any statistical signiﬁcance (p> 0.05). This is
the ﬁrst report analyzing the association between mono-
carboxylate transporter expression and the morphological
features of BRAFV600E mutated papillary thyroid carcinomas
suggesting the possible involvement of lactate in the mor-
phological features.
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Introduction
In the last years, several papers have demonstrated that well
differentiated thyroid carcinomas, mainly the classical var-
iant of papillary thyroid carcinoma (PTC) harbors activating
somatic mutations in v-raf murine sarcoma viral oncogene
homolog B (BRAF) oncogene as demonstrated by its 45–70%
prevalence in PTCs with also prognostic implications [1–5].
Among all BRAF mutations, more than 95 % of them
involve the exon 15 of the B isoform of RAF kinase gene
resulting in a valine to glutamic acid substitution in the
BRAF protein BRAFV600E [1–8]. However several entities,
including the majority of follicular variants (FVPC), folli-
cular and Hurthle cell carcinomas are devoid of this muta-
tion [1–7]. Furthermore the diagnostic and prognostic
signiﬁcance of BRAFV600E mutation in PTCs and/or its
variants is less clear and deﬁned even if a recent multi-
center retrospective review conﬁrmed highly signiﬁcant
increased risk of recurrence, multifocal carcinomas, lymph-
node metastases, and extrathyroidal extension in BRAFV600E
mutated PTC on FNA [8].
Despite the invaluable advantages of DNA-based meth-
ods to assess somatic mutations, the recognition of either
the novel monoclonal BRAFV600E antibody (clone VE1) or
the new insights of the morphological features associated
with BRAFV600E mutation are now subject to increased
investigations [8–15]. Nonetheless, to date, only three
papers, including one from our group, emphasized that
these distinctive morphological features including some
architectural (tumor-associated stromal reaction, inﬁltrative
tumor borders) and cellular speciﬁc parameters (polygonal
eosinophilic cells deﬁned as “plump cells” and sickle-
shaped nuclei) are likely to show high predictive value for
BRAFV600E mutation in PTCs [12–15]. Nevertheless, the
molecular mechanism beneath these morphological ﬁndings
in thyroid carcinomas is not completely known. However,
as previously demonstrated by Hall et al. in BRAFV600E
melanoma cell lines, they pointed to the “Warburg effect”
pioneering the ability of BRAFV600E cancer cells to uphold
the activity of glycolysis providing evidence that oncogene
addiction rests on a strikingly different energetic metabo-
lism. This aerobic glycolysis implies the conversion of
pyruvate to lactic acid leading to a reduction in intracellular
pH [16–18].
The resulting lactate accumulation in BRAFV600E mutated
cells may justify the morphological ﬁndings of abundant
eosinophilic cytoplasm shared by these cells [19, 20]. In
this perspective, monocarboxylate transporters (MCTs),
especially the ﬁrst 4MCTs (MCT1–4), glucose trasporter-
1 (GLUT1), and pH regulator (carbonic anhidrase—
CAIX), play a main role in transporting lactate and other
monocarboxylates across membranes coupled with a proton
as well as in contributing to the extrusion of lactate and the
maintenance of the intracellular pH of tumor cells [21–27].
Despite the fact that the role of MCTs is still far from being
fully deﬁned in cancer, Pinheiro et al. provided some
information in several human tumors like from brain, breast,
sarcomas, uterine cervix [21–27]. Herein, we investigate the
correlation between the morphological ﬁndings associated
with BRAFV600E and MCTs in 48 thyroid cytological cases
diagnosed as “positive for malignancy” and followed by
surgical outcome.
Material and methods
We included all the 48 “positive for malignancy-favoring
PTC (PM)” samples with surgical follow-up in the period
between January 2013 and December 2013 and recorded in
the Division of Pathology in Rome. All Fine needle
aspiration cytology (FNAC) were carried out under-
sonographic guidance (US) mostly by surgeons and endo-
crinologists and processed with liquid-based cytological
(LBC) Thin Prep 5000TM method (Hologic Co., Marlbor-
ough, MA).
Our patients were studied with US during their thyroid
check-up performed in the “Centre for Thyroid Diseases” of
our hospital. The series included 12 male and 36 female
patients with a median age of 27 years (range 19–73 years
old). All aspirations (usually two passes for each lesion)
were performed with 25–27 G needles; no rapid on-site
assessment of the adequacy of the material was done. All
patients had been appropriately informed regarding the use
of LBC method for processing their samples and a written
informed consensus was signed. Our study followed the
tenants of the Declaration of Helsinki receiving the internal
(Catholic University) ethical approval for the study. The
resulting LBC slides were ﬁxed in 95 % methanol and
stained with Papanicolaou, while the remaining material is
stored in the PreservcytTM solution to be used for the pre-
paration of additional slides for further investigations
[including both immunocytochemistry (ICC) and molecular
analysis] as described in our previous papers [11, 14, 28].
The lower limit for the adequacy for each sample was
established according to the British RCPath classiﬁcation,
in six groups of thyroid follicular epithelial cells within the
submitted LBC slides, each of them with at least 10 well-
visualized epithelial cells [29].
The cytological cases were classiﬁed according to the
Italian classiﬁcation which shares several categories with
the Bethesda System for Reporting Thyroid Cytopathology
[30, 31]. All the cytological and histological diagnoses were
evaluated by two expert pathologists (EDR, GF) and those
cases whose interpretation was equivocal were submitted to
the diagnostic judgment of the other pathologists until a
ﬁnal agreement was achieved. According to the deﬁnition of
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plump cells, previously described in our paper and char-
acterized by neoplastic cells displaying homogenous eosi-
nophilic cytoplasms and with their height which was less
than twice their width, we excluded both cases diagnosed as
tall cell variant (TCV) and oxyphilic variant of PTC. Spe-
ciﬁcally, the former entity shows the peculiar predominance
of neoplastic PTC cells whose height was at least three
times their widths, while the latter entity was characterized
by distinctive neoplastic atypical cells with oxyphilic basal
zone, mid-placed nuclei, and slightly clearer apical region
contrasting the homogeneous eosinophilic cytoplasms of
plump cells.
Molecular analysis
DNA was extracted from LBC samples stored in Preserve-
Cyt® solution (Hologic, Marlborough, MA, USA) and from
parafﬁn embedded tissues. The speciﬁc details of our
molecular method on LBC and histology have been accu-
rately detailed in our previous papers [11, 14, 28, 32].
Sensitivity of this method states 5 % in our laboratory. The
following sequence was analyzed: Exon 15: ACAGT/
AGAAA. The percentage of disease speciﬁc cells for
molecular analysis was at least 50 % in all LBC samples.
The BRAF mutational analysis was also performed on DNA
extracted by surgical specimens, containing at least 70 % of
tumor.
Histology
All surgical specimens were ﬁxed in 10 % buffered for-
maldehyde, embedded in parafﬁn and the 5 micron-thick
microtomic sections were stained with hematoxylin and
eosin. All the peri-thyroid adipose tissue was embedded and
examined for the lymph-node research. The diagnosis of
PTC was based on the presence of true papillary structures
and the distinctive nuclear features, whereas the diagnosis
FVPC relied upon the detection of the nuclear features of
PTC in multiple foci within the tumor including both dif-
fuse and encapsulated variants [33]. Encapsulated tumors
with either lympho-vascular invasion (within the capsule or
beyond) or capsular penetration were diagnosed as invasive
FVPCs. TCV was characterized by predominance of neo-
plastic cells whose heights were at least three times their
widths and with classical PTC nuclear features. The oxy-
philic variant of PTC was deﬁned by distinctive neoplastic
cells showing marked cellular atypia with oxyphilic basal
zone, mid-placed nuclei, and slightly clearer apical region.
All cases were classiﬁed according to the seventh edition of
the tumor-node-metastasis-based staging system
recommended by the American Joint Commission on
Cancer (AJCC) [33].
Immunohistochemistry
We retrospectively analyzed all the 48 histological speci-
mens for MCT expression. Immunohistochemistry for
MCT1 was performed according to the avidin-biotin-
peroxidase complex method (R.T.U. VECTASTAIN Elite
ABC kit (Universal), Vector Laboratories, Burlingame, CA)
with primary antibodies for MCT1 (AB3538P Chemicon
International), while MCT4, GLUT1, and CAIX immu-
nostaining was done according to the streptavidin-biotin-
complex principle (Ultravision Detection System Anti-
polyvalent, HRP, LabVision Corporation, Fremont, CA)
with primary antibodies for MCT4 (sc-50329 Santa Cruz
Biotecnology), GLUT1 (ab15309-500 AbCam), and CAIX
(ab15086 AbCam) diluted as previously described (Table 1,
[21–26]). Negative controls were performed by the use of
appropriate serum controls for the primary antibodies,
whereas colon cancer and kidney were used as positive
controls. Reactions were evaluated by two pathologists
(EDR, FS) blinded to the BRAF molecular status and dis-
cordant results were discussed in a multi-head microscope.
The interpretation and validation of application on his-
tology were supported by our previous experience [21–26].
Brieﬂy, the cytoplasm and plasma membrane positivity of
the samples was scored semi-quantitatively as follow: 0:0 %
of cells; 1:<5 % positive cells; 2:5–50 % positive cells; 3:
>50 % positive cells. Also intensity of staining was scored
semi-qualitatively as follows: 0:negative; 1:weak; 2:inter-
mediate; 3:strong. The ﬁnal score was rendered as the sum
of both parameters and grouped as negative (score 0–2) and
positive (score 3–6).
Statistical analysis
Statistical analysis was performed by using a commercially
available statistical software package (SPSS23, Chicago, IL,
USA) for Windows (Microsoft, Redmond, Washington,
USA). Comparison of categorical variables was performed
by χ2 statistic, using the Fisher’s exact test when appro-
priate. A p value lower than 0.05 was considered
signiﬁcant.
Results
All the 48 cyto-histological samples diagnosed as “positive
for malignancy” in the period between January and
December 2013 were analyzed for the expression of the
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MCT isoforms 1 and 4 as well as CAIX and GLUT1.
Table 2 shows the distribution of clinical-pathological fea-
tures in the 33 mutated (69 %) and 15 WT cases (31 %).
Regardless of BRAFV600E mutation, 42 out of 48 nodules
resulted as equal as or smaller than 2 cm size. All the cases
were histological conﬁrmed and diagnosed as 43 classical
variant of PTC and 5 FVPC of papillary thyroid cancer
(including three invasive FVPCs and two encapsulated
FVPCs). The distribution of these histological diagnoses
between mutated and WTs is reported in Table 2. We
excluded all the cases resulted as TCV and oxyphilic PTC at
histology as indicated in the “Material and methods” sec-
tion. Moreover, T-stage (subdivided into into TI–TII and
TIII–TIV) and N-stage did not reach statistical signiﬁcance
in the two groups. Lymph-node metastases were found in
11 out of 33 (33.4 %) BRAFV600E mutated cases and in 6 outT
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Table 2 Clinical-pathological data of PTCs’ patients
Clinical features BRAFV600E BRAF WT
n (%) n (%)
Sex
Male 7 (21.2 %) 5 (33.3 %)
Female 26 (78.8 %) 10 (66.7 %)
Age range (median)
24–74 (45 y.o.) 27–78 (46 y.o.)
Size
<2 cm 30 (91 %) 12 (80 %)
>2 cm 3 (9 %) 3 (20 %)
Cytology
TIR5 33 15
Histology
PTC 31 (94 %) 12 (80 %)
FVPTC 2a (6 %) 3a (20 %)
T-stage
TI–TII 23 (69.7 %) 8 (53.3 %)
TIII–TIV 10 (30.3 %) 7 (46.7 %)
N-stage
pNO 22 (66.6 %) 9 (60 %)
pN1 11 (33.4 %) 6 (40 %)
Plump cells
Absent 0 11
Focal 3 4
Diffuse 30 0
Sickle-shaped nuclei
Present 33 0
All the parameters were not statistical signiﬁcant (p> 0.05)
y.o. years old, WT wild type, PTC papillary thyroid carcinoma, FVPC
follicular variant of PTC, TIR5 positive for malignancy, T-stage tumor
stage, N-stage lymph-node stage
aAll the 2 BRAFV600E mutated FVPCs and 1 WT FVPC were invasive
FVPCs
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of 15 (40 %) WTs. As underlined in Table 2, there were no
statistical signiﬁcant differences in any of the analyzed
parameters (p> 0.05). According to our purpose, we sought
for both the typical nuclear features of papillary thyroid
carcinoma (grooves, pleomorphic membrane, and nuclear
pseudo-inclusions) and the recently described “plump cells”
showing the morphological features of polygonal cells with
abundant eosinophilic cytoplasm (Figs. 1 and 2, 14, 15).
Furthermore, the quantiﬁcation of the plump cell compo-
nent proves that these cells are signiﬁcantly associated with
BRAFV600E mutation (p= 0.0002-OR 70.23 95% CI
3.46–1.427) with only 3 out of 33 (9 %) mutated cases
incurring focal plump cell component belonging to the PTC
histotype [14]. Moreover, we reported 4 out of 15 (27 %)
WT samples with focal plump cell components (Table 1)
diagnosed as PTCs. Sickle-shaped nuclei were found in 100%
of our mutated BRAFV600E and absent in WTs (Table 2). We
reported 100 % concordance for the same peculiar para-
meters in the corresponding histological sections (Fig. 1). In
the group of FVPCs, the two mutated invasive FVPCs
showed both diffuse plump cells and sickle-shaped nuclei
while none of the WT FVPC (diagnosed as two encapsu-
lated and 1 invasive FVPCs) had these morphological
parameters.
Table 3a shows the results of IHC expression for the
metabolism-related markers. We focused our attention on
the correlation between these immunomarkers and
BRAFV600E mutation. In keeping with our previous yields,
we conﬁrmed that the IHC expression of these proteins was
found at the plasma membrane in all the cases but 3 WT
cases with nuclear expression of MCT1. Speciﬁcally,
MCT1 was found positive in 27 cases including 25 mutated
carcinomas (detailed in the table for histotypes) and 2 WTs.
Moreover, the correlation of ICC expression with the
morphological ﬁndings of plump cells and sickle-shaped
nuclei showed moderate to strong MCT1 expression in both
plump cells and sickle-shaped nuclei of all mutated cases
(Fig. 3); on the other hand, only one WT case with focal
plump cells expressed MCT1. Additionally, all the normal
thyroid tissue around the carcinomas showed negative IHC
expression for these immunomarkers. In detail, the peri-
neoplastic thyroid tissue presented 8 hyperplastic nodules
and 2 small follicular adenomas with negative IHC
expression.
The analysis of MCT4 showed 100 % positivity in
mutated cases and 40 % WTs (histotype details in the
Table 3a). The expression was both on the plasma mem-
brane and cytoplasm. In the majority of mutated cases we
found a strong expression (3+) in more than 50 % of the
plump cells and sickle-shaped nuclei (Fig. 4). In the WT
group, apart from four cases with focal plump cells showing
strong expression (3+), we found two additional cases with
moderate expression (2+) in less than 5 % of the cells.
The analysis of CAIX (Fig. 5) and GLUT1 (Fig. 6)
(plasma membrane and cytoplasm) expression was devoid
of statistical signiﬁcance as demonstrated by similar posi-
tivity in 79 % of the 33 mutated, as well as in 87 % of WTs
for the former while GLUT1 was positive in the majority of
cases (88 % mutated and 67 % WTs). We also worked out
that MCT1 demonstrated the highest speciﬁcity (86.7 %)
and positive predictive value (PPV-92 %) while
MCT4 showed 100 % sensitivity and 100 % negative pre-
dictive value (NPV). Lower values have been associated
with CAIX and GLUT1 (speciﬁcity ranging from 13.3 to
33.3 %; NPV between 22.2 and 55.6 % and diagnostic
accuracy between 58.3 and 70.8 %).
In Table 3b, we show the statistical signiﬁcance of the
combination of these immunomarkers. In this regard, we
underscored that all our 33 mutated cases expressed
Fig. 1 Cytological sample of a BRAFV600E mutated cases diagnosed as
“positive for malignancy-favoring PTC”. Evidence of plump cells with
eosinophilic cytoplasms and nuclear features of PTC and evidence of
sickle-shaped nuclei on LCB (LBC, 40X)
Fig. 2 Histological sample from the same cytological case with spe-
ciﬁc histological details of plump cells with details on the sickle-
shaped nuclei (H&E 60X)
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positivity in more than two immunomarkers, while among
the WTs only 4 out of 15 (26 %) had a combined score
equal to or greater than three markers. The speciﬁc dis-
tribution of ICC markers in both mutated and WT cases is
detailed in Table 3b.
Regarding the correlation between the
clinical–pathological features and the expression of the
immunomarkers, we analyzed their implication with some
aggressive parameters, including multifocality, extrathyroid
inﬁltration, and lymph-node metastases; however, none of
Table 3a Association of MCT1, MCT4, CAIX, and GLUT1 expression in thyroid samples
MCT1 MCT4 CAIX GLUT1
+ − + − + − + −
PTC
BRAFV600E 24 (77.5 %) 7 (22.5 %) 31 (100 %) 0 (0 %) 25 (80.6 %) 6 (19.4 %) 28 (90.3 %) 3 (9.7 %)
BRAF WT 1 (8.3 %) 11 (91.7 %) 6 (50 %) 6 (50 %) 11 (91.7 %) 1 (8.3 %) 8 (66.7 %) 4 (33.3 %)
FVPTC
BRAFV600E 1 (50 %) 1 (50 %) 2 (100 %) 0 (0 %) 1 (50 %) 1 (50 %) 1 (50 %) 1 (50 %)
BRAF WT 1 (33.3 %) 2 (66.7 %) 0 (0 %) 3 (100 %) 2 (66.7 %) 1 (33.3 %) 2 (66.7 %) 1 (33.3 %)
WT wild type, PTC papillary thyroid carcinoma, FVPC Follicular variant of PTC
Fig. 3 Positive (plasma membrane) expression of MCT1 in the same
BRAFV600E mutated PTC (ABC 400X)
Fig. 4 Positive (plasma membrane and cytoplasm) expression of
MCT4 in the same BRAFV600E mutated PTC (ABC 400X)
Fig. 5 Positive (plasma membrane and cytoplasm) expression of
CAIX in the same BRAFV600E mutated PTC (ABC 400X)
Fig. 6 Positive (plasma membrane and cytoplasm) expression of
GLUT1 in the same BRAFV600E mutated PTC (ABC 400X)
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the markers reached statistical signiﬁcance as highlighted in
Table 4 (p> 0.05). Firstly, despite the lack of statistical
correlation, we saw that MCT1 and GLUT1 expression was
associated with lymph-node metastases in 59 and 88.2 % of
the cases, respectively. No signiﬁcant associations were
found for CAIX and MCT4 (Table 4). However, the data
highlighted a slightly higher percentage of positive cases
among the cases with higher T-stage (TIII–TIV), metastatic
lymph nodes (pN1) and multifocality (Table 4).
Discussion
The aim of our paper is to evaluate the correlation between
speciﬁc morphological features of BRAFV600E mutation
previously described on PTCs and the alteration of lactate
metabolism through the expression of MCTs and other
metabolism-related proteins.
To date, only few papers have investigated and demon-
strated that PTCs with BRAFV600E mutation have distinctive
morphological features (speciﬁcally plump cells and sickle-
shaped nuclei) which may be easily detected on cytological
and histological samples of thyroid malignant lesions
[12–15]. In fact, in two different papers, Virk et al. and
Finkelstein et al. identiﬁed the presence of large polygonal
tumor cells with homogeneous, eosinophilic, moderate to
abundant cytoplasm with nuclear features of PTC in 72 and
65% of their BRAFV600E mutated PTCs, respectively [12, 13].
According to the data provided by Virk et al. and
Finkelstein et al., we identiﬁed the same plump cells in all
the cases harboring BRAFV600E in both malignant cytolo-
gical and histological thyroid specimens including PTCs
and invasive FVPCs. Notably, in doing so, we discovered a
peculiar sickle shape nuclear morphology in all the
BRAFV600E cases that neither Virk nor Finkelstein had
previously described or reported this ﬁnding in their thyroid
lesions [14, 15]. It is noteworthy that our WTs cases were
completely devoid of these pathognomonic shaped nuclei.
To determine which mechanisms were most essential for
those morphological features, the examination of a possible
involvement of metabolic changes has been suspected.
However, the explanation of the molecular mechanisms
beneath these predictive features of mutation is unlikely to
be completely understood. Since cancer cells up-regulate
glucose metabolism to induce aerobic glycolysis with the
so-called Warburg effect, this may be the springboard of the
possible correlation with altered metabolism in these
“plump” cells and BRAFV600E mutation [17–20].
Using BRAFV600E melanoma cell lines, Hall et al.
demonstrated the addiction to the glycolytic metabolism
promoted by mutated oncogenes through the active sig-
naling pathway driving the up-regulation of genes involved
in glycolysis [17–20]. Equally importantly, the hypergly-
colytic phenotype may pave the way for the use of new
tailored therapeutic strategies in clinical trials of patients
with resistance to radio-iodine therapies.
Therefore we decided to shed light on the hypothesis of
hyperglycolytic phenotype in mutated PTCs by the inves-
tigation of MCTs. Speciﬁcally MCT1 and MCT4, are the
main proteins responsible for the extrusion of lactate, being
their activity essential for the maintenance of the glycolytic
phenotype. In previous reports, the functional role of MCTs
have been revealed as mediating the extrusion of lactate and
Table 3b Combined positive immunomarkers in the 48 samples.
Only plasma membrane expressions were considered
BRAFV600E BRAF WT
4 positive IM 19 1
3 positive IM 9 3
2 positive IM 5 8
1 positive IM 0 2
0 positive IM 0 1
IM immunomarkers
Table 4 Association of MCT1, MCT4, CAIX, GLUT1 with prognostic/aggressive parameters
MCT1 MCT4 CAIX GLUT1
+ − + − + − + −
T-stage
TI–TII 16 (51.6 %) 15 (48.4 %) 25 (80.6) 6 (19.4 %) 24 (77.4 %) 7 (22.6 %) 25 (80.6 %) 6 (19.4 %)
TIII–TIV 9 (53 %) 8 (47 %) 14 (82.3 %) 3 (17.7 %) 15 (88.2 %) 2 (17.8 %) 14 (82.3 %) 3 (17.7 %)
N-stage
pN0 15 (48.4 %) 16 (51.6 %) 25 (80.6 %) 6 (19.4 %) 26 (83.8 %) 5 (16.2 %) 24 (77.4 %) 7 (22.6 %)
pN1 10 (58.8 %) 7 (41.2 %) 14 (82.3 %) 3 (17.7 %) 13 (76.5 %) 4 (23.5 %) 15 (88.2 %) 2 (11.8 %)
Multifocality
Absent 12 (54.5 %) 10 (45.5 %) 16 (72.7 %) 6 (27.3 %) 17 (77.3 %) 5 (22.7 %) 16 (72.7 %) 6 (27.3 %)
Present 13 (50 %) 13 (50 %) 23 (88.5 %) 3 (11.5 %) 22 (84.6 %) 4 (15.4 %) 23 (88.5 %) 3 (11.5 %)
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also contributing to the maintenance of the intracellular pH
of tumor cells of different body sites [21–27, 34–36].
In this regard, the previously investigated analysis of
MCT expression by our group led to useful information
about the prognostic impact of these proteins in several
solid epithelial and mesenchymal tumors including brain,
colon, breast, uterine cervix, lung even though their role in
thyroid carcinomas have never been investigated [21–27,
34–36]. To the best of our knowledge this is the ﬁrst study
in which 48 thyroid PTCs were analyzed for the compara-
tive analysis between MCTs and the morphological ﬁndings
of BRAFV600E mutation. In agreement with the previous
studies, we described MCT expression at the plasma
membrane (MCT1) and cytoplasm of mutated cells
(MCT4), and found nuclear expression in WT cases. In fact,
as previously described by Pinheiro et al. in sarcomas, also
in this series we recognized the nuclear expression of
MCT1, suggesting the existence of an additional role of
MCT1 which may induce a less aggressive behavior in the
thyroid carcinomas [21].
In the present study, both MCT1 and MCT4 highlighted
a correlation with plump cells and sickle-shaped nuclei
deﬁned by 76 and 97.1 % positive expression in the mutated
cases, respectively. Additionally, we documented MCT
expression in cases with focal plump cells, underlying that
these markers recognized speciﬁcally these morphological
features and they may represent a valid aid especially on
cytological samples.
Considering that the high glycolytic rates in cancer cells
lead to accumulation of lactate, the increase of MCT1 and
MCT4 expression in the plasma membrane of plump cells
would support the glycolytic phenotype ending with the
reduction of intracellular acidosis and apoptosis. Hence, the
larger number of mutated plump cells with MCT4 com-
pared to those with MCT1 may justify the different role of
these proteins, as previously clariﬁed [21].
In fact, MCT1 is considered an intermediate afﬁnity
isoform while MCT4 is a low afﬁnity transporter, which
expression has been observed in highly glycolytic tissues
where it is responsible for lactate efﬂux [36]. The detection
of strong and diffuse MCT4 expression in mutated thyroid
PTCs could avoid cellular acidiﬁcation and, as a con-
sequence, promote cell survival and prevention of apopto-
sis. In this regard, we also combined these markers with the
clinic-pathological diagnoses in order to investigate a pos-
sible prediction of their prognostic value. In this perspec-
tive, and as previously done in other papers, we compared
the expression of these markers with T-stage, N-stage, and
multifocality. Nonetheless, the evidence that both MCT1
and MCT4 were able to distinguish between groups with
worse and better prognosis was not appreciated in the pre-
sent work. In fact, we only found a slightly larger number of
MCT1 positive cases with extrathyroid extension
(TIII–TIV) while all the analysis of the remaining 3 markers
did not show any statistical signiﬁcance. Despite the limited
number of cases in our series, this lack of prognostic cor-
relation may imply that, in PTCs, the role of these trans-
porters is linked to BRAF mutation, constituting attractive
targets for cancer tailored therapies.
Concerning CAIX and GLUT1, we did not ﬁnd any
signiﬁcant results allowing the discrimination between
mutated vs. wild type cases. Speciﬁcally CAIX, which is a
HIF-1α(hypoxia-inducible factor 1) target protein as well as
MCT4, overlapped the result of MCT4 expression, high-
lighting the same semi-quantitative results in plump cells
and sickle-shaped nuclei. Actually, the high number of WT
cases with CAIX expression is likely to demonstrate that
this protein is not regulated by the same mechanisms as
MCTs. Moreover, despite the statistical signiﬁcance of
GLUT1 reported in mesotheliomas vs. reactive mesothelial
cells [25], we did not parallel the same signiﬁcant result in
our mutated plump cells vs. WTs. Despite the fact that these
molecular mechanisms are not object of our current paper,
these results clearly support the fact that molecular
mechanisms underlying MCTs need additional studies as
long as MCTs seem to be induced by protein kinase C
(PKC) signaling pathway while MCT1 inhibited by PKA
signaling pathway [27].
In order to overcome the issues of the results obtained
with single immunomarkers, we assessed the correlation
between the morphological features and the entire panel of
immunomarkers. Our data led to the conclusion that the
majority of mutated cases had at least two positive immu-
nomarkers, while there were not a signiﬁcant number of
WTs with more than two positive markers. Together, the
best choice to support the morphology of plump cells seems
to be ascribed to the combined use of MCT1 and MCT4
expression. In fact, these two immunomarkers provided the
highest sensitivity and speciﬁcity, pointing to the pre-
ferential use of concordant positive panel rather than single
markers.
This paper contributes to the suggestion that metabolic
alterations also occur in BRAFV600E thyroid carcinomas and
that the morphological features of mutation are likely to
support the lactate accumulation and the potential involve-
ment of metabolic changes through the glycolytic pathway.
This ﬁrst correlation between MCT expression and mor-
phological features predictive of BRAFV600E mutation in
PTCs may offer the possibility to study the role of speciﬁc
target therapies as an additional aid. However, we are
conscious that larger studies are warranted to conﬁrm our
data.
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